Dr Priyank Pankajkumar Shah, MD - Medicare Cardiovascular Disease (cardiology) in Monroe, NC

Dr Priyank Pankajkumar Shah, MD is a medicare enrolled "Internal Medicine - Cardiovascular Disease" physician in Monroe, North Carolina. He graduated from medical school in 2008 and has 16 years of diverse experience with area of expertise as Cardiovascular Disease (cardiology). He is a member of the group practice The Presbyterian Hospital, Novant Medical Group Inc, Novant Health Matthews Medical Center Llc, Novant Health Mint Hill Medical Center, Llc and his current practice location is 1640 E Roosevelt Blvd, Monroe, North Carolina. You can reach out to his office (for appointments etc.) via phone at (704) 226-0500.

Dr Priyank Pankajkumar Shah is licensed to practice in North Carolina (license number 2023-01353) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1285946988.

Contact Information

Dr Priyank Pankajkumar Shah, MD
1640 E Roosevelt Blvd,
Monroe, NC 28112-4017
(704) 226-0500
(704) 226-0599



Physician's Profile

Full NameDr Priyank Pankajkumar Shah
GenderMale
SpecialityCardiovascular Disease (cardiology)
Experience16 Years
Location1640 E Roosevelt Blvd, Monroe, North Carolina
Accepts Medicare AssignmentsYes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Dr Priyank Pankajkumar Shah graduated from medical school in 2008
  NPI Data:
  • NPI Number: 1285946988
  • Provider Enumeration Date: 07/09/2010
  • Last Update Date: 07/04/2023
  Medicare PECOS Information:
  • PECOS PAC ID: 1052610631
  • Enrollment ID: I20230712000697

Medical Identifiers

Medical identifiers for Dr Priyank Pankajkumar Shah such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1285946988NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207R00000XInternal Medicine 2023-01353 (North Carolina)Secondary
207RC0000XInternal Medicine - Cardiovascular Disease 075366 (Georgia)Secondary
207RC0000XInternal Medicine - Cardiovascular Disease 2023-01353 (North Carolina)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
Novant Health Presbyterian Medical CenterCharlotte, NCHospital
Novant Health Matthews Medical CenterMatthews, NCHospital
Novant Health Mint Hill Medical CenterCharlotte, NCHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
The Presbyterian Hospital1153231907359
Novant Medical Group Inc11532348931996
Novant Health Matthews Medical Center Llc640684524756
Novant Health Mint Hill Medical Center, Llc812337439421

News Archive

American Pain Society urges Congress to resist NIH budget cuts

The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.

BPA "de-masculinizes" male mice: Study

Laboratory studies have shown that male mice who are exposed in the womb to bisphenol A, or BPA, a chemical compound found in some hard plastics and can linings, appear to be less masculine and less attractive to females once they mature. This raises controversies that human boys could be similarly affected. The findings were published Monday on the website of the journal Proceedings of the National Academy of Sciences.

Crossmatch Verifier Sentry handheld solution named Biometric Identification Device of 2015

Crossmatch, a leading provider of livescan enrollment and multi-factor authentication solutions, announced today that the company's Verifier Sentry handheld has been awarded the Biometric Identification Device of 2015 by Government Security News (GSN).

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

Read more Medical News

› Verified 4 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Priyank Pankajkumar Shah allows following entities to bill medicare on his behalf.
Entity NameNovant Medical Group Inc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1366409492
PECOS PAC ID: 1153234893
Enrollment ID: O20031121000692

News Archive

American Pain Society urges Congress to resist NIH budget cuts

The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.

BPA "de-masculinizes" male mice: Study

Laboratory studies have shown that male mice who are exposed in the womb to bisphenol A, or BPA, a chemical compound found in some hard plastics and can linings, appear to be less masculine and less attractive to females once they mature. This raises controversies that human boys could be similarly affected. The findings were published Monday on the website of the journal Proceedings of the National Academy of Sciences.

Crossmatch Verifier Sentry handheld solution named Biometric Identification Device of 2015

Crossmatch, a leading provider of livescan enrollment and multi-factor authentication solutions, announced today that the company's Verifier Sentry handheld has been awarded the Biometric Identification Device of 2015 by Government Security News (GSN).

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

Read more Medical News

› Verified 4 days ago

Entity NameNovant Medical Group Inc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1306950282
PECOS PAC ID: 1153234893
Enrollment ID: O20040204001028

News Archive

American Pain Society urges Congress to resist NIH budget cuts

The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.

BPA "de-masculinizes" male mice: Study

Laboratory studies have shown that male mice who are exposed in the womb to bisphenol A, or BPA, a chemical compound found in some hard plastics and can linings, appear to be less masculine and less attractive to females once they mature. This raises controversies that human boys could be similarly affected. The findings were published Monday on the website of the journal Proceedings of the National Academy of Sciences.

Crossmatch Verifier Sentry handheld solution named Biometric Identification Device of 2015

Crossmatch, a leading provider of livescan enrollment and multi-factor authentication solutions, announced today that the company's Verifier Sentry handheld has been awarded the Biometric Identification Device of 2015 by Government Security News (GSN).

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

Read more Medical News

› Verified 4 days ago

Entity NameThe Presbyterian Hospital
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1053365817
PECOS PAC ID: 1153231907
Enrollment ID: O20040223001121

News Archive

American Pain Society urges Congress to resist NIH budget cuts

The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.

BPA "de-masculinizes" male mice: Study

Laboratory studies have shown that male mice who are exposed in the womb to bisphenol A, or BPA, a chemical compound found in some hard plastics and can linings, appear to be less masculine and less attractive to females once they mature. This raises controversies that human boys could be similarly affected. The findings were published Monday on the website of the journal Proceedings of the National Academy of Sciences.

Crossmatch Verifier Sentry handheld solution named Biometric Identification Device of 2015

Crossmatch, a leading provider of livescan enrollment and multi-factor authentication solutions, announced today that the company's Verifier Sentry handheld has been awarded the Biometric Identification Device of 2015 by Government Security News (GSN).

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

Read more Medical News

› Verified 4 days ago

Entity NameNovant Health Matthews Medical Center Llc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1184782419
PECOS PAC ID: 6406845247
Enrollment ID: O20051114000445

News Archive

American Pain Society urges Congress to resist NIH budget cuts

The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.

BPA "de-masculinizes" male mice: Study

Laboratory studies have shown that male mice who are exposed in the womb to bisphenol A, or BPA, a chemical compound found in some hard plastics and can linings, appear to be less masculine and less attractive to females once they mature. This raises controversies that human boys could be similarly affected. The findings were published Monday on the website of the journal Proceedings of the National Academy of Sciences.

Crossmatch Verifier Sentry handheld solution named Biometric Identification Device of 2015

Crossmatch, a leading provider of livescan enrollment and multi-factor authentication solutions, announced today that the company's Verifier Sentry handheld has been awarded the Biometric Identification Device of 2015 by Government Security News (GSN).

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

Read more Medical News

› Verified 4 days ago

Entity NameNovant Health Mint Hill Medical Center, Llc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1063910404
PECOS PAC ID: 8123374394
Enrollment ID: O20181018000540

News Archive

American Pain Society urges Congress to resist NIH budget cuts

The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.

BPA "de-masculinizes" male mice: Study

Laboratory studies have shown that male mice who are exposed in the womb to bisphenol A, or BPA, a chemical compound found in some hard plastics and can linings, appear to be less masculine and less attractive to females once they mature. This raises controversies that human boys could be similarly affected. The findings were published Monday on the website of the journal Proceedings of the National Academy of Sciences.

Crossmatch Verifier Sentry handheld solution named Biometric Identification Device of 2015

Crossmatch, a leading provider of livescan enrollment and multi-factor authentication solutions, announced today that the company's Verifier Sentry handheld has been awarded the Biometric Identification Device of 2015 by Government Security News (GSN).

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

Read more Medical News

› Verified 4 days ago

Entity NameNovant Health Ballantyne Medical Center Llc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1760190607
PECOS PAC ID: 4880065143
Enrollment ID: O20230518003163

News Archive

American Pain Society urges Congress to resist NIH budget cuts

The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.

BPA "de-masculinizes" male mice: Study

Laboratory studies have shown that male mice who are exposed in the womb to bisphenol A, or BPA, a chemical compound found in some hard plastics and can linings, appear to be less masculine and less attractive to females once they mature. This raises controversies that human boys could be similarly affected. The findings were published Monday on the website of the journal Proceedings of the National Academy of Sciences.

Crossmatch Verifier Sentry handheld solution named Biometric Identification Device of 2015

Crossmatch, a leading provider of livescan enrollment and multi-factor authentication solutions, announced today that the company's Verifier Sentry handheld has been awarded the Biometric Identification Device of 2015 by Government Security News (GSN).

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

Read more Medical News

› Verified 4 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Priyank Pankajkumar Shah is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Dr Priyank Pankajkumar Shah, MD
Po Box 60447,
Charlotte, NC 28260-0447

Ph: (704) 226-0500
Dr Priyank Pankajkumar Shah, MD
1640 E Roosevelt Blvd,
Monroe, NC 28112-4017

Ph: (704) 226-0500

News Archive

American Pain Society urges Congress to resist NIH budget cuts

The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.

BPA "de-masculinizes" male mice: Study

Laboratory studies have shown that male mice who are exposed in the womb to bisphenol A, or BPA, a chemical compound found in some hard plastics and can linings, appear to be less masculine and less attractive to females once they mature. This raises controversies that human boys could be similarly affected. The findings were published Monday on the website of the journal Proceedings of the National Academy of Sciences.

Crossmatch Verifier Sentry handheld solution named Biometric Identification Device of 2015

Crossmatch, a leading provider of livescan enrollment and multi-factor authentication solutions, announced today that the company's Verifier Sentry handheld has been awarded the Biometric Identification Device of 2015 by Government Security News (GSN).

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

Read more News

› Verified 4 days ago


Internal Medicine Doctors in Monroe, NC

Dr. Thomas Joseph Bice, MD
Cardiovascular Disease
Medicare: Accepting Medicare Assignments
Practice Location: 1969 Wellness Blvd, Monroe, NC 28110
Phone: 704-316-5775    Fax: 704-316-5815
Rajiv Paudel, MD
Cardiovascular Disease
Medicare: Accepting Medicare Assignments
Practice Location: 1550 Faulk St, Ste 3100, Monroe, NC 28112
Phone: 704-667-3410    
Charles H Hoover Iii, MD
Cardiovascular Disease
Medicare: Medicare Enrolled
Practice Location: 1420 E Franklin St, Monroe, NC 28112
Phone: 704-289-8427    Fax: 704-283-5522
Pascale Anglade, MD
Cardiovascular Disease
Medicare: Not Enrolled in Medicare
Practice Location: 1663 Campus Park Dr, Suite D, Monroe, NC 28112
Phone: 704-291-2488    Fax: 704-283-0160
Pawan Damodhar Sarda, M.D.
Cardiovascular Disease
Medicare: May Accept Medicare Assignments
Practice Location: 1640 E Roosevelt Blvd, Monroe, NC 28112
Phone: 704-226-0500    Fax: 704-226-0599
Santhosh Reddy Devarapally, MD
Cardiovascular Disease
Medicare: Accepting Medicare Assignments
Practice Location: 1550 Faulk St, Ste 3100, Monroe, NC 28112
Phone: 704-667-3410    
Dr. James Wayne Roberts, MD
Cardiovascular Disease
Medicare: May Accept Medicare Assignments
Practice Location: 1640 E Roosevelt Blvd, Monroe, NC 28112
Phone: 704-226-0500    Fax: 704-226-0599

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.